It should be noted that the inhibitory effect of Fraction B treatment on CD44 expression was initially identified through the unbiased RPPA analysis using human PDAC xenograft tumor tissue samples and was then further validated in vitro using PDAC cell line, suggesting that CD44 might be a true target of Fraction B; however, the detailed molecular mechanisms by which Fraction B inhibits CD44 await for further study. Here, CD44 is linked to neoplasm.